SCHEMBL19684376

SCHEMBL19684376

C#Cc1ccccccccc1C(=O)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.63
TDP1 Q9NUW8 4/20 0.61
KMT2A Q03164 2/20 0.54
SLC6A2 P23975 1/20 0.54
SLC6A3 Q01959 1/20 0.54
L3MBTL1 Q9Y468 5/20 0.54
TSHR P16473 3/20 0.54
CYP3A4 P08684 2/20 0.54
MAPK1 P28482 2/20 0.54
POLB P06746 1/20 0.52
LMNA P02545 2/20 0.50
CASP3 P42574 1/20 0.49
RAB9A P51151 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
NPC1 O15118 1/20 0.49
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19511234 1.00 ALDH1A1 (0.63) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL1655506 0.87 ALDH1A1 (0.55) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL1066455 0.87 ALDH1A1 (0.67) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL16127330 0.84 ALDH1A1 (0.63) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL7553264 0.83 ALDH1A1 (0.50) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL29388715 0.82 ALDH1A1 (0.89) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL50441 0.82 ALDH1A1 (0.89) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL7911356 0.82 ALDH1A1 (0.50) ALDH1A1TDP1KMT2ASLC6A2SLC6A3
SCHEMBL19638940 0.80 TSHR (0.67) ALDH1A1TDP1KMT2AL3MBTL1TSHR
SCHEMBL5273761 0.80 ALDH1A1 (0.58) ALDH1A1TDP1KMT2ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975903-B2 Condensed heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-22 US disclosed
US-20170349605-A1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349605-A1 CONDENSED HETEROCYCLIC COMPOUND VIP, TMPRSS15, MMP2 ALDH1A1 996/4885TDP1 4680/4885KMT2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.